<DOC>
	<DOCNO>NCT00069264</DOCNO>
	<brief_summary>To determine maximum tolerate dose E7389 patient advance solid tumor progress follow standard therapy standard therapy exist .</brief_summary>
	<brief_title>Study E7389 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Patients must histologically cytologically confirm measurable advanced solid tumor progress follow standard therapy standard therapy exists ( include surgery radiation therapy ) Patients may receive prior chemotherapy Patients must age &gt; 18 year Patients must Karnofsky Performance Status &gt; 70 % Patients must life expectancy &gt; 3 month Patients must adequate renal function evidence serum creatinine &lt; 1.5mg/dL creatinine clearance &gt; = 45mL/minute Patients must adequate bone marrow function evidence absolute neutrophil count &gt; 1,500/µL platelet &gt; 100,000/µL Patients must adequate liver function evidence bilirubin &lt; 1.5mg/dL alanine transaminase ( ALAT ) aspartate transaminase ( ASAT ) &lt; = 2 time upper limit normal ( ULN ) unless relate liver involvement tumor , case &lt; = 5.0 time ULN Patients must willing able comply study protocol duration study Patients must give write informed consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice Exclusion Criteria Patients receive chemotherapy within three week ( six week nitrosoureas receive ) E7389 treatment start Patients recover chemotherapy relate therapy relate toxicity study entry Patients require active anticoagulant therapy Women pregnant breastfeeding . Women childbearing potential either positive pregnancy test Screening pregnancy test . Women childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception opinion Investigator ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) Fertile men willing use contraception fertile men female partner willing use contraception Patients successfully complete local therapy previously treat central nervous system ( CNS ) metastases discontinued corticosteroid least four week start treatment E7389 . Patients asymptomatic brain metastasis evidence midline shift CT scan MRI may enrol without initiation local therapy CNS metastasis . In case , repeat scan must perform within four week original scan ensure disease progression occur . Patients test positive HIV Patients severe uncontrolled intercurrent illness/infection ( exclude malignancy ) Patients uncontrolled cardiovascular illness define unstable angina , myocardial infarction within 6 month prior study entry , symptomatic congestive heart failure ( CHF ) ( NYHA II high ) clinical evidence CHF , clinical evidence serious cardiac arrhythmia Patients organ allografts Patients receive investigational drug , include immunotherapy , gene therapy , hormone therapy , biologic therapy ; antineoplastic therapy ; radiation therapy ( require palliation ) within three week E7389 treatment start Patients major surgery within four week E7389 treatment start without full recovery Patients hypersensitivity Halichondrin B and/or Halichondrin Blike compound Patients significant disease , Investigator 's opinion , would exclude patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Metastatic Tumors</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Stage IV Tumors</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Recurrent Solid Tumors</keyword>
</DOC>